Dark

CRBP
Corbus Pharmaceuticals Holdings, Inc.
stock NASDAQ

Market Open

May 26, 2026 3:42:21 PM EDT

7.93USD-30.132%(-3.42)3,443,887

7.00Bid 8.00Ask 1.00Spread

Pre-market

May 26, 2026 9:28:30 AM EDT

9.75USD-14.097%(-1.60)93,028

After-hours

May 22, 2026 4:37:30 PM EDT

11.27USD-0.609%(-0.07)0

OverviewOptionsHistoricalExchangesShortsNews

Dec 26, 2021

09:53AM EST The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year Benzinga

Dec 7, 2021

08:38AM EST Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., As Chief Scientific Officer Benzinga

08:06AM EST Corbus Pharma Appoints Rachael Brake As Chief Scientific Officer RTTNews

08:05AM EST Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific PR Newswire

Nov 12, 2021

08:20AM EST Corbus Pharma Q1 Revenue $97,000 Vs $1.23 Mln Prior Year RTTNews

08:18AM EST Corbus Pharmaceuticals Q3 EPS $(0.02) Up From $(0.43) YoY Benzinga

08:05AM EST Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and PR Newswire

Nov 11, 2021

08:06AM EST Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference PR Newswire

Nov 2, 2021

06:16AM EDT The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 05.55 A.M. EDT). RTTNews

Oct 21, 2021

09:30AM EDT uniQure Announces the Appointment of Rachelle GlobeNewswire Inc

Oct 7, 2021

05:10PM EDT Bullish Sentiment For Marijuana Stocks: Tilray, GrowGeneration & Canopy Growth Among Top Cannabis Movers For October 7, 2021 Benzinga

Aug 12, 2021

09:04AM EDT Recap: Corbus Pharmaceuticals Q2 Earnings Benzinga

08:11AM EDT Corbus Pharmaceuticals Q2 EPS $(0.15) Up From $(0.52) YoY, Sales $137.00K Down From $286.35K YoY Benzinga

08:05AM EDT -- Company focused on gaining regulatory clarity for late-stage lenabasum program and advancing programs targeting the endocannabinoid system and integrins into the clinic -- Augmentingthe pipeline through business development continues to be a priority -- Cash and investments on hand of $114M provides projected runway into first quarter of 2024 GlobeNewswire Inc

Jul 29, 2021

07:01PM EDT Intec Pharma, GreenTree & MedMen Among Top Cannabis Stock Movers On July 29, 2021 Benzinga

Jul 20, 2021

06:03PM EDT Bullish Sentiment Pumps Up Cannabis Stocks: Tilray, Sundial, Aurora & GrowGen Among Top Cannabis Movers For July 20, 2021 Benzinga

Jul 14, 2021

07:14AM EDT General Cannabis, MariMed & Urban-Gro Among Top Cannabis Stock Movers On July 13, 2021 Benzinga

Jul 12, 2021

09:11PM EDT Rhinomed, Zelira And Alcanna Among Top Cannabis Stock Movers On July 12, 2021 Benzinga

Jul 7, 2021

05:33PM EDT Sundial Growers, Cresco Labs, RIV Capital Among Top Cannabis Stock Movers On July 7, 2021 Benzinga

Jul 6, 2021

05:20PM EDT MedMen, Item 9 Labs & EnWave Among Top Cannabis Stock Movers On July 6, 2021 Benzinga

Jun 25, 2021

05:24PM EDT Cannabis Stock Gainers And Losers From June 25, 2021 Benzinga

10:21AM EDT Roth Capital Reiterates Neutral Rating On Corbus Pharmaceuticals Following Negative Phase 3 Trial In Dermatomyositis, $1.79 Price Target. Benzinga

Jun 24, 2021

08:33AM EDT Immunology company Corbus Pharmaceuticals Holdings Inc. (CRBP) announced Thursday topline results from the Phase 3 DETERMINE study of lenabasum in adults with the rare, heterogeneous, autoimmune disease dermatomyositis. RTTNews

08:10AM EDT Corbus Pharma Shares To Resume Trade At 8:35 a.m. EDT Benzinga

08:09AM EDT Corbus: DETERMINE Phase 3 Study Did Not Meet Primary Endpoint Of TIS At Week 28 RTTNews

08:06AM EDT Corbus Pharma Reports Topline Results From DETERMINE Phase 3 Study Of Lenabasum For Treatment Of Dermatomyositis: Says Study Did Not Meet Primary Endpoint Benzinga

08:05AM EDT -- Study did not meet primary endpoint of Total Improvement Score (TIS) at Week 28 -- Additional findings included nominally significant improvements in TIS (p = 0.0302) and CDASI (p = 0.0166) depending on the dermatomyositis subtype -- Lenabasum treatment was safe and well-tolerated in this study GlobeNewswire Inc

08:01AM EDT Corbus Pharma Shares Halted News Pending Benzinga

Jun 17, 2021

04:43PM EDT Cannabis Stock Gainers And Losers From June 17, 2021 Benzinga

Jun 1, 2021

12:26PM EDT Corbus In-Licenses Two Anti-Integrin Antibodies Targeting Cancer, Fibrotic Diseases Settings Benzinga

11:44AM EDT Corbus Pharmaceuticals shares were trading higher after the company announced licenses for two integrim targeting mAbs. Benzinga

07:10AM EDT Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs; Will Pay $2M Up Front And Make Potential Milestones Of Up To $206M Benzinga

07:05AM EDT -- Corbus diversifies pipeline with two new mAbs that target integrins that inhibit activation of TGF GlobeNewswire Inc

May 28, 2021

06:05PM EDT Cannabis Stock Gainers And Losers From May 28, 2021 Benzinga

May 25, 2021

08:07AM EDT Corbus Pharmaceuticals To Present Two Abstracts At EULAR 2021 Virtual Congress Benzinga

08:05AM EDT Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (Corbus or the Company), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the publication of two abstracts at the European League Against Rheumatism (EULAR) 2021 Virtual Congress that will be taking place June 2-5, 2021. GlobeNewswire Inc

May 24, 2021

04:54PM EDT Cannabis Stock Gainers And Losers From May 24, 2021 Benzinga

May 19, 2021

09:21AM EDT Corbus Pharmaceuticals Announces Adjournment Of Annual Meeting Benzinga

May 17, 2021

04:57PM EDT Cannabis Stock Gainers And Losers From May 17, 2021 Benzinga

May 13, 2021

08:50AM EDT Recap: Corbus Pharmaceuticals Q1 Earnings Benzinga

08:27AM EDT Corbus Pharmaceuticals Q1 EPS $(0.14) Up From $(0.43) YoY, Sales $648.00K Down From $1.76M YoY Benzinga

08:05AM EDT Corbus Pharmaceuticals Reports First Quarter 2021 Financial GlobeNewswire Inc

May 11, 2021

08:05AM EDT Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (Corbus or the Company), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be presenting at three upcoming virtual investor conferences. GlobeNewswire Inc

May 6, 2021

05:18PM EDT Cannabis Stock Gainers And Losers From May 6, 2021 Benzinga

Apr 30, 2021

07:27PM EDT Cannabis Stock Gainers And Losers From April 30, 2021 Benzinga

Apr 21, 2021

03:34PM EDT Cannabis Stock Gainers And Losers From February 23, 2021 Benzinga

Apr 20, 2021

08:24AM EDT Corbus Pharmaceuticals Announces Completion Of Enrollment In NIH-Sponsored Phase 2 Study Of Lenabasum For Treatment Of Systemic Lupus Erythematosus Benzinga

08:05AM EDT Corbus Pharmaceuticals Announces Completion of Enrollment in GlobeNewswire Inc

Apr 19, 2021

05:19PM EDT Cannabis Stock Gainers And Losers From April 19, 2021 Benzinga

Mar 30, 2021

08:16AM EDT Corbus Pharmaceuticals Announces Last Subject Visit In DETERMINE Phase 3 Study Of Lenabasum For Treatment Of Dermatomyositis Benzinga

08:05AM EDT -- Topline data on schedule for Q2 2021 -- Dermatomyositis is a rare and life-threatening autoimmune disease characterized by skin and muscle inflammation, and affects ~80,000 people in North America, EU, and Japan -- There is a significant need for safer and more effective treatments in dermatomyositis because of limitations of current treatment options GlobeNewswire Inc

Mar 15, 2021

11:41AM EDT Corbus Pharmaceuticals shares were trading higher after the company reported better-than-expected Q4 EPS results. Benzinga

08:26AM EDT Recap: Corbus Pharmaceuticals Q4 Earnings Benzinga

07:10AM EDT Corbus Pharmaceuticals Q4 EPS $(0.10) Beats $(0.25) Estimate Benzinga

07:05AM EDT Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 GlobeNewswire Inc

04:53AM EDT Earnings Scheduled For March 15, 2021 Benzinga

Mar 14, 2021

08:14AM EDT Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations Benzinga

Mar 9, 2021

08:05AM EST Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (Corbus or the Company), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be presenting at two upcoming virtual investor conferences. GlobeNewswire Inc

Mar 8, 2021

08:46AM EST Company to host conference call and webcast on Monday, March 15, 2021 at 8:30 a.m. ET GlobeNewswire Inc

Mar 5, 2021

03:42PM EST Three Ways To Approach The Cannabis Trade Benzinga

Feb 23, 2021

05:44PM EST Cannabis Stock Gainers And Losers From February 23, 2021 Benzinga

Feb 10, 2021

04:23PM EST The Week In Cannabis: Stocks Up By Double-Digits On Jazz Pharma's GWPH Acquisition, Potential Federal Moves Benzinga

Feb 2, 2021

10:44AM EST ROCE Insights For Corbus Pharmaceuticals Benzinga

Jan 20, 2021

08:06AM EST Corbus Pharmaceuticals Announces Presentations At The New York Academy Of Sciences Webinar On Targeting The Endocannabinoid System To Treat Human Diseases Benzinga

08:05AM EST -- Presentations about compounds in Corbus pipeline will highlight mechanistic studies of lenabasum, a CB2 agonist, and preclinical data from CB2 agonist oncology program and CB1 inverse agonist metabolism program GlobeNewswire Inc

Jan 19, 2021

08:01AM EST The Little-Known Tech That Could Transform Healthcare PR Newswire

Dec 22, 2020

04:44PM EST Cannabis Stock Gainers And Losers From December 22, 2020 Benzinga

Dec 1, 2020

10:28AM EST Looking Into Corbus Pharmaceuticals's Return On Capital Employed Benzinga

Nov 16, 2020

09:54AM EST ROCE Insights For Corbus Pharmaceuticals Benzinga

Nov 12, 2020

08:05AM EST -- Fireside chat with live audio webcast on Thursday, November 19th at 12:35 PM EST GlobeNewswire Inc

Nov 10, 2020

08:40AM EST The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga

07:33AM EST Corbus Pharmaceuticals: Q3 Earnings Insights Benzinga

07:05AM EST Corbus Pharmaceuticals Reports Third Quarter Financial Results and GlobeNewswire Inc

Nov 9, 2020

10:27AM EST Corbus Pharmaceuticals's Earnings: A Preview Benzinga

08:10AM EST Corbus Pharmaceuticals Presents Additional Data From RESOLVE-1 Study In Systemic Sclerosis; Co Says 'Topline data remain as previously reported' Benzinga

08:05AM EST Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 GlobeNewswire Inc

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 4, 2020

05:33PM EST Cannabis Stock Gainers And Losers From November 4, 2020 Benzinga

Nov 3, 2020

08:05AM EST -- Company to host conference call and webcast on Tuesday, November 10 at 8:30 a.m. ET GlobeNewswire Inc

Oct 23, 2020

08:40AM EDT Stocks Trading Near 52-Week Lows Before Open On Friday, Oct. 23, 2020: CRBP, YGMZ, ITRM, BBI Benzinga

08:08AM EDT Corbus Pharmaceuticals Announces Presentation Of Data From Phase 2b Study In Cystic Fibrosis At NACFC 2020 Benzinga

08:05AM EDT Corbus Pharmaceuticals Announces Presentation of Data from its GlobeNewswire Inc

Oct 22, 2020

11:42AM EDT Corbus Pharmaceuticals Option Alert: Jan 15 $1 Calls at the Ask: 1200 @ $0.201 vs 1359 OI; Earnings 11/5 Before Open [est] Ref=$1.0 Benzinga

Oct 21, 2020

08:09AM EDT Corbus Pharmaceuticals Announces Three Lenabasum Abstracts To Be Presented At ACR Convergence 2020 Benzinga

08:05AM EDT Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be GlobeNewswire Inc

08:04AM EDT The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings Benzinga

Oct 20, 2020

08:17AM EDT The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger Benzinga

Oct 8, 2020

08:44AM EDT 10 Biggest Price Target Changes For Thursday Benzinga

08:23AM EDT Corbus Pharmaceuticals Announces Corporate Restructuring And Pipeline Portfolio Updates Benzinga

08:17AM EDT Corbus Pharmaceuticals Holdings, Inc. (CRBP) announced a restructuring of its workforce to reallocate capital to certain clinical and preclinical programs. This will result in a reduction of its workforce by 54%. The company is implementing cost reductions with the objective of extending its cash runway to mid-2022. RTTNews

08:09AM EDT Corbus Plans Restructuring That Will Result In Reduction Of Workforce By 54% RTTNews

08:05AM EDT -- Company is restructuring with the goal of extending cash runway to mid-2022 -- Workforce to be reduced by 54% -- Company to focus on completing Phase 3 dermatomyositis study and advancing preclinical pipeline into the clinic GlobeNewswire Inc

07:04AM EDT HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $3 Benzinga

Oct 6, 2020

02:34PM EDT Mid-Afternoon Market Update: Dow Surges 150 Points; Alteryx Shares Spike Higher Benzinga

12:32PM EDT Mid-Day Market Update: Crude Oil Rises Over 3%; Miragen Therapeutics Shares Slide Benzinga

07:31AM EDT Corbus Pharmaceuticals Holdings, Inc. (CRBP) announced Tuesday that the CF-002 Phase 2b study of lenabasum in patients with cystic fibrosis (CF) did not meet the primary endpoint of a statistically significant reduction in rate of new pulmonary exacerbations (PEx) per subject per 28 weeks. RTTNews

07:09AM EDT Corbus Pharma Says Phase 2b Study Of Lenabasum Fails To Meet Primary Endpoint RTTNews

07:08AM EDT Corbus Pharmaceuticals Announces Phase 2b Study Of Lenabasum For Treatment Of Cystic Fibrosis Did Not Meet Primary Endpoint; Shares Halted Ahead Of Announcement Benzinga

07:05AM EDT -- Study did not meet primary endpoint of reducing rate of pulmonary exacerbations -- Lenabasum treatment had a favorable safety profile and was well-tolerated -- Data to be presented at the upcoming North American Cystic Fibrosis Conference Oct. 7-23 GlobeNewswire Inc

Sep 9, 2020

07:50AM EDT HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $6 Benzinga

Sep 8, 2020

02:33PM EDT Mid-Afternoon Market Update: Dow Falls 1.5%; Nikola Shares Surge Benzinga

01:58PM EDT Corbus Pharmaceuticals Shares Tick Lower; Jefferies Downgrades From Buy To Hold, Reduces Price Target From $18 To $2.50 Benzinga

12:39PM EDT Roth Capital Downgrades Corbus Pharmaceuticals to Neutral Benzinga

12:36PM EDT BTIG Downgrades Corbus Pharmaceuticals to Neutral Benzinga

12:34PM EDT RBC Capital Downgrades Corbus Pharmaceuticals to Sector Perform Benzinga

12:00PM EDT Mid-Day Market Update: Nasdaq Tumbles Over 300 Points; Co-Diagnostics Shares Spike Higher Benzinga

10:22AM EDT Mid-Morning Market Update: Markets Open Lower; Grifols To Buy Geriatric Pharma Startup Alkahest Benzinga

07:32AM EDT Corbus Pharmaceuticals Holdings Inc. (CRBP), a clinical-stage drug development company, announced Tuesday that its 52-week Phase 3 RESOLVE-1 study of lenabasum in patients with diffuse cutaneous systemic sclerosis or SSc did not meet its primary endpoint. RTTNews

07:16AM EDT Corbus Pharma Says RESOLVE-1 Trial Did Not Meet Its Primary Endpoint RTTNews

07:08AM EDT Corbus Pharmaceuticals Announces Topline Results From RESOLVE-1 Phase 3 Study Of Lenabasum; Says Data Showed 'no significant differences in the primary and secondary endpoints when comparing lenabasum to placebo, both added to background drug therapy.' Benzinga

07:05AM EDT Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 GlobeNewswire Inc

Sep 2, 2020

01:41PM EDT The Pure US Cannabis ETF Started Trading Today: Here Are Its Holdings Benzinga

Aug 14, 2020

10:31AM EDT Looking Into Corbus Pharmaceuticals's Return On Capital Employed Benzinga

Aug 6, 2020

07:32AM EDT Corbus Pharmaceuticals Q2 EPS $(0.52) Misses $(0.39) Estimate Benzinga

07:05AM EDT -- RESOLVE-1 Phase 3 study of lenabasum for treatment of systemic sclerosis on schedule for topline data this summer -- Phase 2b study of lenabasum for cystic fibrosis topline results on schedule in Q3 2020 -- Balance sheet strengthened with up to $121M in new capital -- Company to host conference call and webcast today, August 6, 2020 at 8:30 a.m. ET GlobeNewswire Inc

Aug 5, 2020

08:30PM EDT Cannabis Stock Gainers And Losers From August 5, 2020 Benzinga

09:25AM EDT -- 12-month, double-blind, placebo-controlled, multi-national study enrolled 176 participants -- Topline results expected infourth quarter of 2021 -- Dermatomyositis is a rare, systemic autoimmune disease with characteristic skin and muscle involvement, serious morbidity, and increased mortality GlobeNewswire Inc

Aug 3, 2020

08:05AM EDT Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (Corbus or the Company), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at two upcoming conferences. GlobeNewswire Inc

Jul 30, 2020

08:05AM EDT -- Management to host conference call and webcast on Thursday, August 6 at 8:30 a.m. ET GlobeNewswire Inc

Jul 29, 2020

08:14AM EDT Corbus Pharma Reports $101M In Cash On Hand Expected To Fund Operations In Q3'21 Benzinga

08:13AM EDT UPDATE: Corbus Pharma Reports Aggregate Of $71M Of At The Market Proceeds Executed At Weighted Average $7.70/Share Benzinga

08:13AM EDT Corbus Pharma Says Received $20M First Tranche From $50M Debt Facility With K2 HealthVentures Benzinga

08:12AM EDT Corbus Pharma Reports Aggregate Of $71M Of At The Market Proceeds Executed At Weighted Average $7.70/Share Benzinga

08:08AM EDT Corbus Pharmaceuticals Says Has Received Aggregate Of $71M In Gross Proceeds From At-The-Market Offering Benzinga

08:05AM EDT -- Aggregate of $71 million of ATM proceeds executed at weighted average price of $7.70 per share -- Received $20 million first tranche from $50 million debt facility with K2 HealthVentures -- Cash on hand of $101 million expected to fund operations into third quarter of 2021 -- Provides strategic flexibility post Phase 3 systemic sclerosis topline data readout later this summer GlobeNewswire Inc

Jul 17, 2020

09:50AM EDT Corbus Pharmaceuticals shares are trading higher potentially due to a media report highlighting that the company will be publishing data on its phase 3 clinical trial this summer. Benzinga

08:17AM EDT 'Corbus Pharma is nearing the readout of a pivotal drug study. Here's what you need to know' -STAT Benzinga

Jul 13, 2020

05:11PM EDT Cannabis Stock Gainers And Losers From July 13, 2020 Benzinga